Summary:
- The article discusses the development and evaluation of a novel mRNA vaccine candidate against COVID-19 that targets the SARS-CoV-2 spike protein.
- The vaccine candidate was found to be safe and immunogenic in preclinical studies, inducing robust humoral and cellular immune responses in animal models.
- The authors suggest that this mRNA vaccine candidate holds promise as a potential COVID-19 vaccine and warrants further clinical evaluation.